A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

I2L-MC-ALCA -

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who have mild cognitive impairment due to Alzheimer's Disease (AD) and those with mild-to-moderate AD.

Trial Summary

Age Range
≥20 years
Conditions the trial is for
What the trial is testing?
Could I receive a Placebo?
Yes
Enrollment Goal
50
Trial Dates
Dec 1, 2015 - Dec 1, 2016
How long will I be in the trial?
Your participation could last up to 22 weeks and include 34 visits to the study center.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.